Proactive Investors - Run By Investors For Investors

Allergy Therapeutics set to begin phase II trial of PQ Grass hay fever treatment “imminently”

The allergy vaccine specialist has received regulatory approval to start the phase II trial
hay fever sufferer
AGY reckons PQ Grass, if it gets through the clinic, could generate sales of up to US$300mln a year

Allergy Therapeutics plc (LON:AGY) moved highert today on news it is set to kick off the phase II clinical trial of its hay fever treatment “imminently” after the pharma group got the necessary approvals from authorities.

In late afternoon trading, the firm's shares were up 2.8%, or 0.88p at 32.38p.

The AIM-quoted group believes PQ Grass has the potential to cure grass pollen-induced hay fever, or allergic rhinitis as it’s known in medical circles.

The trial will take place in Germany, Poland and Austria and will involve around 440 patients.

Results from the study are expected in the second half of next year.

Could be worth US$300mln a year to AGY

Should it pass through the clinical stage successfully, Allergy expects the US market to be the main market for the product.

That market alone is estimated to be worth around US$2bn a year and the company is looking at generating peak annual sales of US$300mln from PQ Grass.

If it does get approval, it will be the first subcutaneous (a short needle which injects the drug under the skin) immunotherapy registered in the States.

“This revised Phase II trial will prepare the ground for entry in to the high value US market in which PQ Grass has the potential to become a convenient, best in class, ultra-short course subcutaneous immunotherapy,” said chief executive Manuel Llobet.

“We look forward to reporting headline data next year as we advance this product.”

 -- Adds share price --

View full AGY profile View Profile

Allergy Therapeutics PLC Timeline

Related Articles

November 07 2018
'I joke that Wall Street and Big Pharma didn't wake up today wondering where that next $10 million Canadian product is going to come from, but we do,' says CEO Doug Janzen
surgeons working
September 03 2018
Chief executive Steve Couldwell also told investors the regenerative medicines specialist had identified a number of potential new commercial opportunities it was “actively pursuing”
September 25 2018
The drug developer had originally to recruit 80 people for the second part of its phase II study of its SNG001 treatment, but it will now assess 120 patients

© Proactive Investors 2018

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use